Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9485844 | 0.83 | MAPK8 (0.47) | TDP1MAPK8HPGDKMT2AALDH1A1 | |
| SCHEMBL9485849 | 0.83 | MAPK8 (0.47) | TDP1MAPK8HPGDKMT2AALDH1A1 | |
| SCHEMBL9485837 | 0.83 | MAPK8 (0.47) | TDP1MAPK8HPGDKMT2AALDH1A1 | |
| SCHEMBL20818012 | 0.81 | TDP1 (1.00) | TDP1MAPK8KMT2AALDH1A1MAPT | |
| SCHEMBL9041828 | 0.81 | KMT2A (0.46) | TDP1MAPK8HPGDKMT2AALDH1A1 | |
| SCHEMBL5752212 | 0.80 | TDP1 (0.67) | TDP1MAPK8KMT2AALDH1A1DRD1 | |
| SCHEMBL9122123 | 0.79 | TDP1 (0.66) | TDP1KMT2AMAPT | |
| SCHEMBL1009800 | 0.79 | KMT2A (0.48) | MAPK8HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL7367341 | 0.78 | TDP1 (0.61) | TDP1MAPK8HPGDALDH1A1PKM | |
| SCHEMBL10976046 | 0.77 | TDP1 (0.67) | TDP1MAPK8KMT2AALDH1A1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1817300-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | TDP1 4318/4885MAPK8 2967/4885HPGD 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.